Published in Clin Cancer Res on May 01, 2001
Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov (2012) 4.30
Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol (2006) 2.16
GK-1 improves the immune response induced by bone marrow dendritic cells loaded with MAGE-AX in mice with melanoma. J Immunol Res (2014) 1.48
Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer (2004) 1.39
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
New flow cytometric assays for monitoring cell-mediated cytotoxicity. Expert Rev Vaccines (2010) 1.18
NK cells: key to success of DC-based cancer vaccines? Oncologist (2012) 0.98
Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. Virology (2008) 0.94
Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res (2013) 0.92
Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion. Immunol Res (2010) 0.86
Filamentous bacteriophage fd as an antigen delivery system in vaccination. Int J Mol Sci (2012) 0.85
Development of an artificial-antigen-presenting-cell-based assay for the detection of low-frequency virus-specific CD8(+) T cells in whole blood, with application for measles virus. Clin Vaccine Immunol (2009) 0.82
Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. Cancer Biol Ther (2011) 0.82
Immunogenic comparison of chimeric adenovirus 5/35 vector carrying optimized human immunodeficiency virus clade C genes and various promoters. PLoS One (2012) 0.81
Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays. Biomed Res Int (2013) 0.80
Targeting cytotoxic T lymphocytes for cancer immunotherapy. Br J Cancer (2004) 0.80
Superantigen-SEA gene modified tumor vaccine for hepatocellular carcinoma: an in vitro study. World J Gastroenterol (2004) 0.80
Immunomonitoring in glioma immunotherapy: current status and future perspectives. J Neurooncol (2015) 0.79
Triggering DTH and CTL activity by fd filamentous bacteriophages: role of CD4+ T cells in memory responses. J Biomed Biotechnol (2010) 0.78
Therapeutic Potential of Cell Penetrating Peptides (CPPs) and Cationic Polymers for Chronic Hepatitis B. Int J Mol Sci (2015) 0.78
Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment. Cancer Biol Ther (2011) 0.77
Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. J Clin Immunol (2004) 0.76
Induction/engineering, detection, selection, and expansion of clinical-grade human antigen-specific CD8 cytotoxic T cell clones for adoptive immunotherapy. J Biomed Biotechnol (2010) 0.76
Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide. Int J Cancer (2016) 0.75
Effect of nutritional supplements on immune function and body weight in malnourished adults. Nutr Metab Insights (2010) 0.75
An overview of gene therapy in head and neck cancer. Indian J Hum Genet (2013) 0.75
A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer (2002) 0.75
Generation of murine tumor cell lines deficient in MHC molecule surface expression using the CRISPR/Cas9 system. PLoS One (2017) 0.75
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science (1991) 10.53
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet (1986) 5.05
Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci U S A (1987) 3.47
Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res Hum Retroviruses (1988) 2.99
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol (2009) 2.74
Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci U S A (1987) 2.53
Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol (2001) 2.01
Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med (1992) 1.93
Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. Science (1992) 1.76
Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res (1999) 1.73
Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res (2001) 1.71
Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. Proc Natl Acad Sci U S A (1987) 1.70
Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res (2000) 1.68
Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol (1998) 1.64
Ambulatory surgical management of breast carcinoma using paravertebral block. Ann Surg (1995) 1.62
Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J Virol (2001) 1.58
HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J Immunol (1989) 1.57
Chemoprevention of esophageal tumorigenesis by dietary administration of lyophilized black raspberries. Cancer Res (2001) 1.56
Selective cell transplantation using bioabsorbable artificial polymers as matrices. J Pediatr Surg (1988) 1.55
Use of paravertebral block anesthesia in the surgical management of breast cancer: experience in 156 cases. Ann Surg (1998) 1.43
Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. Lancet (1988) 1.38
Effects of ThermH2Osorb carbon dioxide absorber on temperature and humidity in the anesthetic circuit. Anesth Analg (1997) 1.38
Liver metastases from breast cancer: long-term survival after curative resection. Surgery (2000) 1.38
GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody. J Immunol (1989) 1.29
Mimosine targets serine hydroxymethyltransferase. J Biol Chem (1996) 1.28
A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res (1999) 1.28
A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood (2000) 1.26
Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol (2000) 1.23
Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol (1990) 1.21
HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res (1994) 1.20
Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother (1998) 1.19
Derivation of a biologically contained replication system for human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 1.18
Rapid single-dose model for lung tumor induction in A/J mice by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and the effect of diet. Carcinogenesis (1989) 1.16
Inhibition of N-nitrosomethylbenzylamine-induced tumorigenesis in the rat esophagus by dietary freeze-dried strawberries. Carcinogenesis (2001) 1.09
Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb Haemost (2000) 1.09
GRID: a novel Grb-2-related adapter protein that interacts with the activated T cell costimulatory receptor CD28. J Immunol (2000) 1.06
Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood (2000) 1.06
Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. Cancer Res (2000) 1.06
Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther (2009) 1.05
Anti-HIV-1 ADCC. AIDS Res Hum Retroviruses (1989) 1.05
Quantitation of human uptake of the anticarcinogen phenethyl isothiocyanate after a watercress meal. Cancer Epidemiol Biomarkers Prev (1993) 1.02
Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol (2012) 1.02
Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. AIDS Res Hum Retroviruses (2000) 1.00
The p85 subunit of phosphoinositide 3-kinase is associated with beta-catenin in the cadherin-based adhesion complex. Biochem J (2001) 0.99
Superantigens: the good, the bad, and the ugly. Exp Biol Med (Maywood) (2001) 0.99
Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer (2009) 0.98
Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res (1998) 0.98
Defining origins of replication in mammalian cells. Biochim Biophys Acta (1994) 0.98
Isothiocyanates and plant polyphenols as inhibitors of lung and esophageal cancer. Cancer Lett (1997) 0.97
Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. Br J Cancer (2011) 0.96
Inhibition of N'-nitrosonornicotine-induced esophageal tumorigenesis by 3-phenylpropyl isothiocyanate. Carcinogenesis (1998) 0.96
Phenotypic and functional consequences of herpesvirus saimiri infection of human CD8+ cytotoxic T lymphocytes. J Virol (1993) 0.96
Surgical management of chronic pulmonary embolism. Ann Surg (1985) 0.95
Inhibition of tobacco-specific nitrosamine-induced lung tumorigenesis by compounds derived from cruciferous vegetables and green tea. Ann N Y Acad Sci (1993) 0.93
Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery (1994) 0.93
Distribution and metabolism of the natural anticarcinogen phenethyl isothiocyanate in A/J mice. Carcinogenesis (1990) 0.92
The IFN pregnancy recognition hormone IFN-tau blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J Immunol (1995) 0.92
Immunotherapy of cancer using cytokine gene-modified tumor vaccines. Semin Cancer Biol (1994) 0.92
Isothiocyanates and freeze-dried strawberries as inhibitors of esophageal cancer. Toxicol Sci (1999) 0.91
Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging. Abdom Imaging (1997) 0.91
MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Cancer Res (1996) 0.91
Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model. Anticancer Res (2001) 0.91
Development of a yeast trihybrid screen using stable yeast strains and regulated protein expression. Biotechniques (1998) 0.91
AIDS-related malignancies. Ann Med (1998) 0.90
Utility of Doppler color flow imaging for identification of femoral arterial complications of cardiac catheterization. Am Heart J (1989) 0.90
Staging of pancreatic cancer before and after neoadjuvant chemoradiation. J Gastrointest Surg (2002) 0.90
Pneumatosis intestinalis after lung transplant. Abdom Imaging (2005) 0.89
Cytochromes P450 are expressed in proliferating cells in Barrett's metaplasia. Neoplasia (1999) 0.89
Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mouse lung microsomes and its inhibition by isothiocyanates. Cancer Res (1990) 0.89
Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer (1999) 0.89
Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus. Surgery (1992) 0.88
Quantitating therapeutically relevant T-cell responses to cancer vaccines. Crit Rev Immunol (2001) 0.87
ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. Clin Exp Immunol (2010) 0.87
Chemoprevention with theaflavins of rat esophageal intraepithelial neoplasia quantitatively monitored by image tile analysis. Cancer Epidemiol Biomarkers Prev (2000) 0.85
Expression of cytochrome P450 2A3 in rat esophagus: relevance to N-nitrosobenzylmethylamine. Carcinogenesis (1999) 0.85
Type I interferon induction of the Cdk-inhibitor p21WAF1 is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line. Oncogene (1998) 0.84
Cellular immune response to viral peptides in patients exposed to HIV. AIDS Res Hum Retroviruses (1988) 0.84
Surrogate markers of response to cancer immunotherapy. Expert Opin Biol Ther (2001) 0.84
IFNgamma inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21WAF1/CIP1. Oncogene (1998) 0.84
Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery (1993) 0.83
Clinical applications of dendritic cell vaccines. Curr Opin Mol Ther (2000) 0.83
Effects of cyclosporine on human B-cell lymphoma development in vivo. Surg Oncol (1992) 0.83
New potential chemopreventive agents for lung carcinogenesis of tobacco-specific nitrosamine. Cancer Res (1992) 0.82
Effect of alkyl chain length on inhibition of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis and DNA methylation by isothiocyanates. Carcinogenesis (1995) 0.82
Enhancement of esophageal carcinogenesis in male F344 rats by dietary phenylhexyl isothiocyanate. Carcinogenesis (1995) 0.81
A/J mouse lung tumorigenesis by the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its inhibition by arylalkyl isothiocyanates. Exp Lung Res (1991) 0.81
T cells or active Epstein-Barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice. Ann Surg Oncol (1994) 0.81